Valproate-doxorubicin: Promising therapy for progressing mesothelioma. A phase II study

European Respiratory Journal

Volumn 37, Issue 1, 2011, Pages 129-135

  Scherpereel, A ^a,b   Berghmans, T ^c   Lafitte, J J ^a,b   Colinet, B ^d   Richez, M ^e   Bonduelle, Y ^f   Meert, A P ^c   Dhalluin, X ^a   Leclercq, N ^c   Paesmans, M ^c   Willems, L ^g   Sculier, J P ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c JULES BORDET INSTITUTE   (Belgium)

^d Medical Laboratory Grand Hôpital de Charleroi   (Belgium)

^e Clinique Saint Joseph at Mons   (Belgium)

^f CHR St Joseph ^*  (Belgium)

^g UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Chemotherapy; Doxorubicin; Histone deacetylase inhibitors; Mesothelioma; Valproic acid

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PEMETREXED; VALPROIC ACID;

ADULT; AGED; ALOPECIA; APOPTOSIS; ARTICLE; BLEEDING; BLOOD TOXICITY; BRAIN DISEASE; BRAIN EMBOLISM; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CELL; CONSTIPATION; DEATH; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG FATALITY; FEBRILE NEUTROPENIA; FEMALE; HEARING LOSS; HUMAN; INFECTION; LEUKOPENIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OCCLUSIVE CEREBROVASCULAR DISEASE; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PLEURA; PRIORITY JOURNAL; SKIN INFECTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 79251559363     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00037310     Document Type: Article

References (32)

1. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-495.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
3. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European organisation for research and treatment of cancer lung cancer group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-6889.
4. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008; 26: 1698-1704.
5. Harvey VJ, Slevin ML, Ponder BA, et al. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 1984; 54: 961-964.
6. Sorensen PG, Bach F, Bork E, et al. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 1985; 69: 1431-1432.
7. Sorensen JB, Sundstrom S, Perell K, et al. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2007; 2: 147-152.
8. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009; 63: 94-97.
9. Fennell DA, Steele JP, Shamash J, et al. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer 2007; 109: 93-99.
10. Narasimhan SR, Yang L, Gerwin BI, et al. Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am J Physiol 1998; 275: L165-L171.
11. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009; 69: 1911-1934.
12. Stimson L, Wood V, Khan O, et al. HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 2009; 20: 1293-1302.
13. Marks PA, Richon VM, Breslow R, et al. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13: 477-483.
14. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-6978.
15. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003; 2: 404-409.
16. Knupfer MM, Pulzer F, Schindler I, et al. Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro. Anticancer Res 2001; 21: 347-351.
17. Feng WH, Kenney SC. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 2006; 66: 8762-8769.
18. Friedmann I, Atmaca A, Chow KU, et al. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. J Chemother 2006; 18: 415-420.
19. Catalano MG, Poli R, Pugliese M, et al. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 2007; 14: 839-845.
20. Sakajiri S, Kumagai T, Kawamata N, et al. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005; 33: 53-61.
21. Kaiser M, Zavrski I, Sterz J, et al. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006; 91: 248-251.
22. Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol 2010; 5: 275-279.
23. Vandermeers F, Hubert P, Delvenne P, et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009; 15: 2818-2828.
24. Atmaca A, Al-Batran SE, Maurer A, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007; 97: 177-182.
25. Munster P, Marchion D, Bicaku E, et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009; 15: 2488-2496.
26. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 2005; 4: 22.
27. Rocca A, Minucci S, Tosti G, et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009; 100: 28-36.
28. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
29. Crisanti MC, Wallace AF, Kapoor V, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 2009; 8: 2221-2231.
30. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006; 7: 257-261.
31. Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009; 4: 97-101.
32. Blaheta RA, Michaelis M, Natsheh I, et al. Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer 2007; 96: 1699-1706.